Changeflow GovPing Healthcare & Life Sciences Tetrapeptide Compositions for Treating Eye Diso...
Routine Notice Added Final

Tetrapeptide Compositions for Treating Eye Disorders

Favicon for changeflow.com USPTO Patent Grants - Peptides (C07K)
Published
Detected
Email

Summary

The USPTO granted patent US12605422B2 to S.I.S SHULOV INNOVATIVE SCIENCE LTD. on April 21, 2026, covering tetrapeptide pharmaceutical compositions for treating degenerative, age-related, and trauma-induced disorders of the eye. The patent, application number 17762984, was filed September 23, 2020, and contains 20 claims classified under CPC codes A61K 38/07, A61P 25/28, and C07K 5/1024.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

USPTO granted patent US12605422B2 to S.I.S SHULOV INNOVATIVE SCIENCE LTD. for pharmaceutical compositions comprising specific tetrapeptides for use in treating, preventing, minimizing, diminishing or reversing degenerative, age-related, and trauma-induced disorders, particularly of the eye.

Pharmaceutical and biotechnology companies developing peptide-based therapeutics for ophthalmic conditions should review this patent to assess potential freedom-to-operate implications. The tetrapeptide compositions covered by the 20 granted claims represent enforceable intellectual property that may affect R&D programs targeting similar eye disorder treatments.

Archived snapshot

Apr 21, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Grants

Compositions and methods for treating degenerative, age-related and trauma-induced disorders

Grant US12605422B2 Kind: B2 Apr 21, 2026

Assignee

S.I.S SHULOV INNOVATIVE SCIENCE LTD.

Inventors

Naftali Primor

Abstract

Pharmaceutical compositions comprising specific tetrapeptides, for use in treating, preventing, minimizing, diminishing or reversing degenerative, age-related and trauma-induced disorders, particularly of the eye, are provided.

CPC Classifications

A61K 38/07 A61P 25/28 C07K 5/1024

Filing Date

2020-09-23

Application No.

17762984

Claims

20

View original document →

Get daily alerts for USPTO Patent Grants - Peptides (C07K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 21st, 2026
Instrument
Notice
Branch
Executive
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US12605422B2

Who this affects

Applies to
Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent granting Intellectual property
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals

Get alerts for this source

We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!